TriSalus Life Sciences, Inc.
For the period ended Dec 31, 2025. Filed Mar 5, 2026.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2025 · Filed Mar 5, 2026
TLSI$2.85-11.5%Stored close · as of Nov 10, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Consolidated Statements of Stockholders’ D
Consolidated Statements of Stockholders' Deficit
(in thousands, except share data)
| Preferred stock · Common stock · Additionalpaid-incapital · Accumulateddeficit · Total | |||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Shares · Amount · Shares · Amount | |||||||||||||||||
| Balance as of December 31, 2023 | 4,015,002 | $— | 26,413,213 | $2 | $222,437 | $(249,504) | $(27,065) | ||||||||||
| Net loss | — | — | — | — | — | (30,045) | (30,045) | ||||||||||
| Exercise of options and vesting of restricted stock units (1) | — | — | 180,778 | — | 76 | — | 76 | ||||||||||
| Stock-based compensation | — | — | — | — | 5,441 | — | 5,441 | ||||||||||
| Proceeds from sale of common stock | — | — | 2,542,262 | 1 | 15,474 | — | 15,475 | ||||||||||
| Record exchange warrants | — | — | — | — | 11,924 | — | 11,924 | ||||||||||
| Record issuance costs | — | — | — | — | (1,700) | — | (1,700) | ||||||||||
| Issuance of common stock for exchange warrants | — | — | 2,110,366 | — | — | — | — | ||||||||||
| Preferred stock conversion | (30,000) | — | 32,645 | — | — | — | — | ||||||||||
| Balance as of December 31, 2024 | 3,985,002 | $— | 31,279,264 | $3 | $253,652 | $(279,549) | $(25,894) | ||||||||||
| Net loss | — | — | — | — | — | (39,227) | (39,227) | ||||||||||
| Exercise of options and vesting of restricted stock units (1) | — | — | 466,329 | — | 510 | — | 510 | ||||||||||
| Issuance of common stock through employee stock purchase plan (1) | — | — | 105,609 | — | 404 | — | 404 | ||||||||||
| Stock-based compensation (2) | — | — | — | — | 9,755 | — | 9,755 | ||||||||||
| Proceeds from sale of common stock | — | — | 5,500,000 | — | 20,451 | — | 20,451 | ||||||||||
| Preferred stock conversion | (3,985,002) | — | 12,646,634 | 1 | 11,946 | (11,947) | — | ||||||||||
| Prior period adjustment | — | — | — | — | — | 140 | 140 | ||||||||||
| Balance as of December 31, 2025 | — | $— | 49,997,836 | $4 | $296,718 | $(330,583) | $(33,861) | ||||||||||
| (1) The Company records the issuance of the shares when they are recorded by the transfer agent and as such, there could be timing differences between when the expense is recorded and shares are transferred. | |||||||||||||||||
| (2) Amount includes $0.6 million related to 2024 bonus paid in 2025 in the form of stock-based compensation. | |||||||||||||||||
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.